Breaking News
Sort by:
Top Post
Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease
An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]
Nanoscope Therapeutics Announces Positive Topline Results from Phase 2b RESTORE Trial of MCO-010 for the Treatment of Retinitis Pigmentosa
Nanoscope Therapeutics, today announced topline results from the Phase 2b multicenter, randomized, double-masked, sham-controlled RESTORE […]
Nanoscope Therapeutics Appoints Industry Veteran Vicente Anido Jr., Ph.D., as a Strategic Advisor
Nanoscope Therapeutics, a clinical-stage biotechnology company developing gene therapies for retinal degenerative diseases, today announced […]
Nanoscope Therapeutics Receives Fast Track Designation by the FDA for MCO-010 for the Treatment of Stargardt Disease
Nanoscope Therapeutics, a clinical-stage biotechnology company developing gene therapies for retinal degenerative diseases, today announced […]
Nanoscope Therapeutics Appoints Michael Marquez as Chief Financial Officer
Nanoscope Therapeutics, Inc., a clinical-stage biotechnology company developing gene therapies to treat retinal degenerative diseases, […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more